Please login to the form below
Licensing deals
This page shows the latest Licensing deals news and features for those working in and with pharma, biotech and healthcare.
Amgen and Synaffix sign licensing agreement worth up to $2bn
Earlier this month, Synaffix entered into a licensing agreement with Hummingbird Bioscience, which has also been given access to the company’s ADC technologies. ... The business model of Synaffix is target-specific technology out-licensing, shown
Latest news
-
Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
In June, Merck completed the spin-off of women’s health company Organon, freeing up approximately $9bn for new deals and collaborations. ... Executing value-enhancing business development is a top priority, and we intend to add to our pipeline through
-
Gilead swoops on Forty Seven with $4.9bn all-cash deal
Takeover is latest in a string of billion-plus deals signed by Gilead. ... The takeover is the latest in a string of big billion dollar-plus licensing and acquisition deals signed by Gilead since the start of 2019 under new chief executive Daniel
-
Takeda buys coeliac disease partner PvP Biologics after phase 1 win
There has been a flurry of licensing deals in the coeliac disease area in recent months, including deals between GlaxoSmithKline and Sitari and Roche/Genentech and Parvus, as drugmakers eye a
-
Boehringer bolsters NASH pipeline with Enleofen link-up
It’s the first licensing deal for the company and is also thought to be the largest ever agreed by a Singapore biotech, with Boehringer agreeing to pay up to 1bn ( ... a series of licensing deals as well as its in-house research.
-
AstraZeneca launches $1bn Chinese investment fund
generic products, over a ten-year period, and has agreed licensing deals for three early-stage cancer drugs with Chinese biotech firms.
More from news
Approximately 2 fully matching, plus 88 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
the pipeline, the use of technology in medicine is expected to grow and so are the associated deals, mergers and acquisitions. ... They also can help identify collaboration opportunities including partnerships, licensing deals and merger or acquisition
-
20 for 2020 – Five pharma leaders to watch in 2020
returns. That includes an exit from areas like neurology – which predates Bourla’s appointment as CEO but was set up while he was COO – and a series of bolt-on deals ... Meanwhile, Galapagos looks set to continue adding to its pipeline through
-
A market-adapted agile approach to launch excellence
Furthermore, increases. in region or market-specific licensing deals for launch products have led companies to devolve to region-specific cross-functional teams for tailored launch preparation, allowing different thinking to
-
The changing nature of approvals – what does the future hold?
Mega-mergers are also becoming less frequent; instead, we’re seeing fewer but larger deals. ... Based on CMR International data, since 2015 we have seen the number of drug commercialisation/licensing deals continue to gradually decline while the
-
Deal Watch October 2018
Licensing &. research. collaboration. $550m. Novartis/. Mylan. TOBI Podhaler and TOBI solution for cystic fibrosis. ... Licensing &. collaboration. $40m. All deals are for worldwide rights unless stated otherwise:.
More from intelligence
Approximately 0 fully matching, plus 33 partially matching documents found.
Latest appointments
-
Ablynx appoints Markus Ewert as chief business officer
Edwin Moses, CEO of Ablynx, said: “Markus brings extensive experience in leading business development teams and executing licensing deals and acquisitions.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- FDA external report recommends actions to address US opioid crisis
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Congress is in session – how companies are boosting their impact and engagement
- AstraZeneca announces major expansion of Canadian research footprint
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
